StreetInsider.com News Articles

CARMAT Provides an Update on the Ongoing Receivership Procedure

Fri, 01 Aug 2025 08:00:00 -0400

One takeover bid within the context of a sales plan1 has been received by the judiciary administrator
Resumption of CARMAT shares trading starting on August 4, 2025, at stock market opening

PARIS--(BUSINESS WIRE)-- Regulatory News:

Update on the ongoing receivership procedure

On July

CARMAT Provides an Update on the Ongoing Receivership Procedure

Fri, 01 Aug 2025 08:00:00 -0400

One takeover bid within the context of a sales plan1 has been received by the judiciary administrator
Resumption of CARMAT shares trading starting on August 4, 2025, at stock market opening

PARIS--(BUSINESS WIRE)-- Regulatory News:

Update on the ongoing receivership procedure

On July

CARMAT Provides an Update on the Ongoing Receivership Procedure

Fri, 01 Aug 2025 08:00:00 -0400

One takeover bid within the context of a sales plan1 has been received by the judiciary administrator
Resumption of CARMAT shares trading starting on August 4, 2025, at stock market opening

PARIS--(BUSINESS WIRE)-- Regulatory News:

Update on the ongoing receivership procedure

On July

CARMAT Provides an Update on the Ongoing Receivership Procedure

Fri, 01 Aug 2025 08:00:00 -0400

One takeover bid within the context of a sales plan1 has been received by the judiciary administrator
Resumption of CARMAT shares trading starting on August 4, 2025, at stock market opening

PARIS--(BUSINESS WIRE)-- Regulatory News:

Update on the ongoing receivership procedure

On July

CARMAT Provides an Update on Its Situation and the Ongoing Receivership Procedure

Tue, 29 Jul 2025 12:00:00 -0400

Trading of CARMAT shares suspended, starting July 30, 2025, before stock market opening, ahead of the deadline of July 31, 2025 for submitting takeover or investment offers

PARIS--(BUSINESS WIRE)-- Regulatory News:

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today provides an update on its situation and the ongoing receivership procedure and announces the suspension of trading in CARMAT shares, starting July 30, 2025, before stock market opening, ahead of the deadline of July

CARMAT Provides an Update on Its Situation and the Ongoing Receivership Procedure

Tue, 29 Jul 2025 12:00:00 -0400

Trading of CARMAT shares suspended, starting July 30, 2025, before stock market opening, ahead of the deadline of July 31, 2025 for submitting takeover or investment offers

PARIS--(BUSINESS WIRE)-- Regulatory News:

CARMAT Provides an Update on Its Situation and the Ongoing Receivership Procedure

Tue, 29 Jul 2025 12:00:00 -0400

Trading of CARMAT shares suspended, starting July 30, 2025, before stock market opening, ahead of the deadline of July 31, 2025 for submitting takeover or investment offers

PARIS--(BUSINESS WIRE)-- Regulatory News:

CARMAT Provides an Update on Its Situation and the Ongoing Receivership Procedure

Tue, 29 Jul 2025 12:00:00 -0400

Trading of CARMAT shares suspended, starting July 30, 2025, before stock market opening, ahead of the deadline of July 31, 2025 for submitting takeover or investment offers

PARIS--(BUSINESS WIRE)-- Regulatory News:

CARMAT receives updated CE marking for Aeson artificial heart

Mon, 28 Jul 2025 12:00:26 -0400

CARMAT (Euronext Growth: ALCAR) announced it obtained CE marking under the Medical Devices Regulation for its Aeson artificial heart system. The updated certification covers the bridge to transplant indication and applies to Aeson as a Class III active implantable medical device.

The MDR CE marking was granted by notified body DEKRA following a comprehensive review. This certification replaces CARMAT's previous CE marking obtained in December 2020 under the Medical Device Directive, which has since been superseded by stricter MDR requirements.

Class III medical devices that received CE marking under the former directive before May 2021 have until May 2027 to obtain MDR

CARMAT receives updated CE marking for Aeson artificial heart

Mon, 28 Jul 2025 12:00:26 -0400

Class III medical devices that received CE marking under the former directive before May 2021 have until May 2027 to obtain MDR

CARMAT Receives MDR CE Marking for Its Aeson® Artificial Heart

Mon, 28 Jul 2025 12:00:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces that it has obtained CE marking under Regulation (EU) 2017/745 on medical devices (Medical Devices Regulation – MDR), which replaces the former Medical Device Directive (MDD 93/42/EEC). This new certification covers the bridge to transplant (BTT) indication and applies to the Aeson® system as a Class III active implantable medical device.

MDR CE marking certifies Aeson®’s compliance with the most stringent

CARMAT Receives MDR CE Marking for Its Aeson® Artificial Heart

Mon, 28 Jul 2025 12:00:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces that it has obtained CE marking under Regulation (EU) 2017/745 on medical devices (Medical Devices Regulation – MDR), which replaces the former Medical Device Directive (MDD 93/42/EEC). This new certification covers the bridge to transplant (BTT) indication and applies to the Aeson® system as a Class III active implantable medical device.
MDR CE marking certifies Aeson®’s compliance with the most stringent

CARMAT Receives MDR CE Marking for Its Aeson® Artificial Heart

Mon, 28 Jul 2025 12:00:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces that it has obtained CE marking under Regulation (EU) 2017/745 on medical devices (Medical Devices Regulation – MDR), which replaces the former Medical Device Directive (MDD 93/42/EEC). This new certification covers the bridge to transplant (BTT) indication and applies to the Aeson® system as a Class III active implantable medical device.
MDR CE marking certifies Aeson®’s compliance with the most stringent

CARMAT Receives MDR CE Marking for Its Aeson® Artificial Heart

Mon, 28 Jul 2025 12:00:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces that it has obtained CE marking under Regulation (EU) 2017/745 on medical devices (Medical Devices Regulation – MDR), which replaces the former Medical Device Directive (MDD 93/42/EEC). This new certification covers the bridge to transplant (BTT) indication and applies to the Aeson® system as a Class III active implantable medical device.
MDR CE marking certifies Aeson®’s compliance with the most stringent

CARMAT Announces the Initiation of a Call for Public Tenders (Buyers or Investors) as Part of the Receivership Procedure

Thu, 03 Jul 2025 12:30:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces the initiation of a call for public tenders (buyers or investors)1 as part of the receivership procedure2 opened on July 1, 2025.
A notice will be published in “Les Echos” French newspaper by the judiciary administrator appointed by the Versailles Economic Affairs Court3 (AJRS – Maître Philippe Jeannerot), on July 4, 2025. The Notice will however be available in the digital

CARMAT Announces the Initiation of a Call for Public Tenders (Buyers or Investors) as Part of the Receivership Procedure

Thu, 03 Jul 2025 12:30:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces the initiation of a call for public tenders (buyers or investors)1 as part of the receivership procedure2 opened on July 1, 2025.
A notice will be published in “Les Echos” French newspaper by the judiciary administrator appointed by the Versailles Economic Affairs Court3 (AJRS – Maître Philippe Jeannerot), on July 4, 2025. The Notice will however be available in the digital

CARMAT Announces the Initiation of a Call for Public Tenders (Buyers or Investors) as Part of the Receivership Procedure

Thu, 03 Jul 2025 12:30:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces the initiation of a call for public tenders (buyers or investors)1 as part of the receivership procedure2 opened on July 1, 2025.
A notice will be published in “Les Echos” French newspaper by the judiciary administrator appointed by the Versailles Economic Affairs Court3 (AJRS – Maître Philippe Jeannerot), on July 4, 2025. The Notice will however be available in the digital

CARMAT Announces the Initiation of a Call for Public Tenders (Buyers or Investors) as Part of the Receivership Procedure

Thu, 03 Jul 2025 12:30:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces the initiation of a call for public tenders (buyers or investors)1 as part of the receivership procedure2 opened on July 1, 2025.
A notice will be published in “Les Echos” French newspaper by the judiciary administrator appointed by the Versailles Economic Affairs Court3 (AJRS – Maître Philippe Jeannerot), on July 4, 2025. The Notice will however be available in the digital

CARMAT Announces Its Placement in Receivership Procedure

Tue, 01 Jul 2025 10:00:00 -0400

Resumption of CARMAT shares trading starting July 2, 2025, at stock market opening

PARIS--(BUSINESS WIRE)-- Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces its placement in receivership procedure1 as well as the resumption of CARMAT shares trading, starting July 2, 2025, at stock market opening.
Opening of receivership procedure
On June 30, 2025, CARMAT had announced in a press release filing for insolvency and requesting to be placed in receivership to the

CARMAT Announces Its Placement in Receivership Procedure

Tue, 01 Jul 2025 10:00:00 -0400

Resumption of CARMAT shares trading starting July 2, 2025, at stock market opening

PARIS--(BUSINESS WIRE)-- Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces its placement in receivership procedure1 as well as the resumption of CARMAT shares trading, starting July 2, 2025, at stock market opening.
Opening of receivership procedure
On June 30, 2025, CARMAT had announced in a press release filing for insolvency and requesting to be placed in receivership to the

CARMAT Announces Its Placement in Receivership Procedure

Tue, 01 Jul 2025 10:00:00 -0400

Resumption of CARMAT shares trading starting July 2, 2025, at stock market opening

PARIS--(BUSINESS WIRE)-- Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces its placement in receivership procedure1 as well as the resumption of CARMAT shares trading, starting July 2, 2025, at stock market opening.
Opening of receivership procedure
On June 30, 2025, CARMAT had announced in a press release filing for insolvency and requesting to be placed in receivership to the

CARMAT Announces Its Placement in Receivership Procedure

Tue, 01 Jul 2025 10:00:00 -0400

Resumption of CARMAT shares trading starting July 2, 2025, at stock market opening

PARIS--(BUSINESS WIRE)-- Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces its placement in receivership procedure1 as well as the resumption of CARMAT shares trading, starting July 2, 2025, at stock market opening.
Opening of receivership procedure
On June 30, 2025, CARMAT had announced in a press release filing for insolvency and requesting to be placed in receivership to the

CARMAT Announces Filing Today for Insolvency and Requesting Being Placed in Receivership

Mon, 30 Jun 2025 01:00:00 -0400

Suspension of CARMAT shares trading starting June 30, 2025, before stock market opening

PARIS--(BUSINESS WIRE)-- Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces filing for insolvency1 and requesting to be placed in receivership2 to the Versailles Economic Affairs Court3, as well as the suspension of CARMAT shares trading, starting June 30, 2025, before stock market opening.
Insolvency filing and request to be placed in receivership
On June 20, 2025, CARMAT announced in

CARMAT Announces Filing Today for Insolvency and Requesting Being Placed in Receivership

Mon, 30 Jun 2025 01:00:00 -0400

Suspension of CARMAT shares trading starting June 30, 2025, before stock market opening

PARIS--(BUSINESS WIRE)-- Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces filing for insolvency1 and requesting to be placed in receivership2 to the Versailles Economic Affairs Court3, as well as the suspension of CARMAT shares trading, starting June 30, 2025, before stock market opening.
Insolvency filing and request to be placed in receivership
On June 20, 2025, CARMAT announced in

CARMAT Announces Filing Today for Insolvency and Requesting Being Placed in Receivership

Mon, 30 Jun 2025 01:00:00 -0400

Suspension of CARMAT shares trading starting June 30, 2025, before stock market opening

PARIS--(BUSINESS WIRE)-- Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces filing for insolvency1 and requesting to be placed in receivership2 to the Versailles Economic Affairs Court3, as well as the suspension of CARMAT shares trading, starting June 30, 2025, before stock market opening.
Insolvency filing and request to be placed in receivership
On June 20, 2025, CARMAT announced in